Genomics BioSci & Tech.Ltd Past Earnings Performance
Past criteria checks 0/6
Genomics BioSci & Tech.Ltd's earnings have been declining at an average annual rate of -23.9%, while the Biotechs industry saw earnings growing at 15.8% annually. Revenues have been declining at an average rate of 0.3% per year.
Key information
-23.9%
Earnings growth rate
-19.8%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | -0.3% |
Return on equity | -22.0% |
Net Margin | -42.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?
Apr 27Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its Dividend
Jan 19Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Nov 25Revenue & Expenses Breakdown
How Genomics BioSci & Tech.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 396 | -168 | 145 | 56 |
30 Sep 23 | 401 | -121 | 147 | 50 |
30 Jun 23 | 405 | -75 | 148 | 44 |
31 Mar 23 | 412 | -2 | 141 | 40 |
31 Dec 22 | 419 | 72 | 134 | 36 |
30 Sep 22 | 411 | 58 | 123 | 29 |
30 Jun 22 | 402 | 45 | 111 | 23 |
31 Mar 22 | 396 | 32 | 116 | 20 |
31 Dec 21 | 390 | 19 | 121 | 17 |
30 Sep 21 | 408 | 31 | 127 | 20 |
30 Jun 21 | 426 | 44 | 133 | 22 |
31 Mar 21 | 434 | 22 | 130 | 22 |
31 Dec 20 | 443 | 1 | 126 | 23 |
30 Sep 20 | 454 | 7 | 126 | 23 |
30 Jun 20 | 465 | 14 | 127 | 24 |
31 Mar 20 | 447 | 16 | 121 | 27 |
31 Dec 19 | 428 | 18 | 116 | 30 |
30 Sep 19 | 408 | -1 | 117 | 33 |
30 Jun 19 | 388 | -20 | 118 | 36 |
31 Mar 19 | 382 | -28 | 121 | 41 |
31 Dec 18 | 375 | -36 | 124 | 45 |
30 Sep 18 | 397 | -31 | 131 | 50 |
30 Jun 18 | 418 | -27 | 138 | 55 |
31 Mar 18 | 429 | -31 | 140 | 50 |
31 Dec 17 | 440 | -36 | 141 | 45 |
30 Sep 17 | 401 | -45 | 137 | 38 |
30 Jun 17 | 362 | -55 | 133 | 31 |
31 Mar 17 | 369 | -50 | 131 | 30 |
31 Dec 16 | 376 | -44 | 130 | 28 |
30 Sep 16 | 397 | -37 | 124 | 25 |
30 Jun 16 | 418 | -30 | 117 | 23 |
31 Mar 16 | 409 | -30 | 111 | 21 |
31 Dec 15 | 401 | -30 | 105 | 19 |
30 Sep 15 | 379 | -31 | 103 | 18 |
30 Jun 15 | 357 | -32 | 101 | 17 |
31 Mar 15 | 337 | -32 | 100 | 23 |
31 Dec 14 | 317 | -33 | 99 | 29 |
30 Sep 14 | 287 | -41 | 97 | 34 |
30 Jun 14 | 257 | -49 | 96 | 39 |
31 Mar 14 | 243 | -58 | 93 | 32 |
31 Dec 13 | 230 | -68 | 91 | 26 |
Quality Earnings: 4195 is currently unprofitable.
Growing Profit Margin: 4195 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4195 is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare 4195's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4195 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.7%).
Return on Equity
High ROE: 4195 has a negative Return on Equity (-21.95%), as it is currently unprofitable.